{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:38:23Z","timestamp":1791805103126,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03081-3","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:22:24Z","timestamp":1787840544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9487-1744","authenticated-orcid":false,"given":"Marta","family":"Krawczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudyna","family":"Fidyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-1080","authenticated-orcid":false,"given":"Narcis","family":"Fernandez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-3284","authenticated-orcid":false,"given":"Tomasz","family":"Winiarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-8040","authenticated-orcid":false,"given":"Monika","family":"Pepek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2969-008X","authenticated-orcid":false,"given":"Pablo","family":"Bousquets-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-1483","authenticated-orcid":false,"given":"Xose S.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-8843","authenticated-orcid":false,"given":"Ana","family":"Guti\u00e9rrez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0309-3800","authenticated-orcid":false,"given":"Daria","family":"Owczarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Graczyk-Jarzynka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9851-5597","authenticated-orcid":false,"given":"Pablo","family":"Sanz-Galarreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-3422","authenticated-orcid":false,"given":"Anna","family":"Szumera-Cie\u0107kiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Benard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-1746","authenticated-orcid":false,"given":"S\u00e9bastien","family":"W\u00e4lchli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2206","authenticated-orcid":false,"given":"Andrei","family":"Thomas-Tikhonenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor M.","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2682-9664","authenticated-orcid":false,"given":"V\u00edctor","family":"Gal\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Escudero L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Izquierdo","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Minguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-9195","authenticated-orcid":false,"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5605-3329","authenticated-orcid":false,"given":"Magdalena","family":"Winiarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"3081_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"3081_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"3081_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"3081_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"Abramson","year":"2020","unstructured":"Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet Lond Engl. 2020;396:839\u201352.","journal-title":"Lancet Lond Engl"},{"key":"3081_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"3081_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103.","journal-title":"Lancet Oncol"},{"key":"3081_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet. 2021;398:491\u2013502.","journal-title":"The Lancet"},{"key":"3081_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","volume":"14","author":"J Lemoine","year":"2021","unstructured":"Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. J Hematol OncolJ Hematol Oncol. 2021;14:199.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"3081_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. 2023;22:976\u201395.","journal-title":"Nat Rev Drug Discov"},{"key":"3081_CR10","doi-asserted-by":"publisher","first-page":"e00383","DOI":"10.1128\/MCB.00383-18","volume":"38","author":"A Bagashev","year":"2018","unstructured":"Bagashev A, Sotillo E, Tang C-HA, Black KL, Perazzelli J, Seeholzer SH, et al. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol. 2018;38:e00383\u201318.","journal-title":"Mol Cell Biol"},{"key":"3081_CR11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"3081_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"3081_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40:187\u201395.","journal-title":"J Immunother"},{"key":"3081_CR14","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1021\/acs.biochem.9b00808","volume":"58","author":"JR Klesmith","year":"2019","unstructured":"Klesmith JR, Wu L, Lobb RR, Rennert PD, Hackel BJ. Fine epitope mapping of the CD19 extracellular domain promotes design. Biochemistry. 2019;58:4869\u201381.","journal-title":"Biochemistry"},{"key":"3081_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf1426","volume":"8","author":"C He","year":"2023","unstructured":"He C, Mansilla-Soto J, Khanra N, Hamieh M, Bustos V, Paquette AJ, et al. CD19 CAR antigen engagement mechanisms and affinity tuning. Sci Immunol. 2023;8:eadf1426.","journal-title":"Sci Immunol"},{"key":"3081_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","volume":"34","author":"M Asnani","year":"2020","unstructured":"Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34:1202\u20137.","journal-title":"Leukemia"},{"key":"3081_CR17","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1182\/blood-2023-185074","volume":"142","author":"J Noble","year":"2023","unstructured":"Noble J, Locke FL, Savid-Frontera C, Jain MD, Turner JG, Abraham Miranda J, et al. CD19 intron retention is a mechanism of CAR-T treatment resistance in non-Hodgkin lymphoma. Blood. 2023;142:3506.","journal-title":"Blood"},{"key":"3081_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31818-y","volume":"13","author":"M Cort\u00e9s-L\u00f3pez","year":"2022","unstructured":"Cort\u00e9s-L\u00f3pez M, Schulz L, Enculescu M, Paret C, Spiekermann B, Quesnel-Valli\u00e8res M, et al. High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance. Nat Commun. 2022;13:5570.","journal-title":"Nat Commun"},{"key":"3081_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood.2021014840","volume":"140","author":"C Bueno","year":"2022","unstructured":"Bueno C, Barrera S, Bataller A, Ortiz-Maldonado V, Elliot N, O\u2019Byrne S, et al. CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood. 2022;140:38\u201344.","journal-title":"Blood"},{"key":"3081_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21168-6","volume":"12","author":"T Rabilloud","year":"2021","unstructured":"Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun. 2021;12:865.","journal-title":"Nat Commun"},{"key":"3081_CR21","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1002\/ajh.25235","volume":"93","author":"J Rosenthal","year":"2018","unstructured":"Rosenthal J, Naqvi AS, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, et al. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. Am J Hematol. 2018;93:E352\u2013E355.","journal-title":"Am J Hematol"},{"key":"3081_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390.","journal-title":"Immunity"},{"key":"3081_CR23","first-page":"3153","volume":"141","author":"ME Selli","year":"2023","unstructured":"Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu Y-S, et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood. 2023;141:3153\u201365.","journal-title":"Blood"},{"key":"3081_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","volume":"18","author":"X Zhao","year":"2020","unstructured":"Zhao X, Yang J, Zhang X, Lu X-A, Xiong M, Zhang J, et al. Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia. Mol Ther Oncolytics. 2020;18:272\u201381.","journal-title":"Mol Ther Oncolytics"},{"key":"3081_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28:415\u201328.","journal-title":"Cancer Cell"},{"key":"3081_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10:702\u201323.","journal-title":"Cancer Discov"},{"key":"3081_CR27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","volume":"26","author":"OO Oluwole","year":"2020","unstructured":"Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B cell lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2020;26:1581\u20138.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"3081_CR28","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354.","journal-title":"Nat Med"},{"key":"3081_CR29","doi-asserted-by":"publisher","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, et al. Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30:584.e1\u2013e13.","journal-title":"Transplant Cell Ther"},{"key":"3081_CR30","first-page":"4921","volume":"24","author":"H-H Cao","year":"2020","unstructured":"Cao H-H, Wang L-L, Geng C-K, Mao W-W, Yang L-L, Ma Y, et al. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): a meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24:4921\u201330.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3081_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","volume":"30","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-el-Enein M. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther. 2023;30:845\u201354.","journal-title":"Cancer Gene Ther"},{"key":"3081_CR32","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/j.clml.2020.12.010","volume":"21","author":"S Aamir","year":"2021","unstructured":"Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes. Clin Lymphoma Myeloma Leuk. 2021;21:e334\u2013e347.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3081_CR33","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/jpm12060881","volume":"12","author":"V Gal\u00e1n-G\u00f3mez","year":"2022","unstructured":"Gal\u00e1n-G\u00f3mez V, Matamala N, Ruz-Caracuel B, Valle-Sim\u00f3n P, Ochoa-Fern\u00e1ndez B, Guerra-Garc\u00eda P, et al. Advanced molecular characterisation in relapsed and refractory paediatric acute leukaemia, the key for personalised medicine. J Pers Med. 2022;12:881.","journal-title":"J Pers Med"},{"key":"3081_CR34","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015;17:405\u201324.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"3081_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/10430340252898984","volume":"13","author":"C Demaison","year":"2002","unstructured":"Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus- forming virus promoter. Hum Gene Ther. 2002;13:803\u201313.","journal-title":"Hum Gene Ther"},{"key":"3081_CR36","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1093\/bioinformatics\/btab141","volume":"37","author":"E Mancini","year":"2021","unstructured":"Mancini E, Rabinovich A, Iserte J, Yanovsky M, Chernomoretz A. ASpli: integrative analysis of splicing landscapes through RNA-Seq assays. Bioinforma Oxf Engl. 2021;37:2609\u201316.","journal-title":"Bioinforma Oxf Engl"},{"key":"3081_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-182","volume":"15","author":"H Jiang","year":"2014","unstructured":"Jiang H, Lei R, Ding S-W, Zhu S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics. 2014;15:182.","journal-title":"BMC Bioinformatics"},{"key":"3081_CR38","unstructured":"Babraham Bioinformatics - FastQC: a quality control tool for high-throughput sequence data. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"3081_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139.","journal-title":"Nat Methods"},{"key":"3081_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3081_CR41","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 2024;52:D672\u2013D678.","journal-title":"Nucleic Acids Res"},{"key":"3081_CR42","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u2013W97.","journal-title":"Nucleic Acids Res"},{"key":"3081_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907\u201315.","journal-title":"Nat Biotechnol"},{"key":"3081_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. GigaScience. 2021;10:giab008.","journal-title":"GigaScience"},{"key":"3081_CR45","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138:1081\u20135.","journal-title":"Blood"},{"key":"3081_CR46","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1182\/bloodadvances.2022007705","volume":"6","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Landmann JH, Carter A, Cooper ML, Selli ME, Chang J, et al. Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies. Blood Adv. 2022;6:5634\u201340.","journal-title":"Blood Adv"},{"key":"3081_CR47","doi-asserted-by":"publisher","first-page":"e001150","DOI":"10.1136\/jitc-2020-001150","volume":"8","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Chen X, Tian Y, Li F, Zhao X, Liu J, et al. Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. J Immunother Cancer. 2020;8:e001150.","journal-title":"J Immunother Cancer"},{"key":"3081_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood.2021015008","volume":"140","author":"MD Jain","year":"2022","unstructured":"Jain MD, Ziccheddu B, Coughlin CA, Faramand R, Griswold AJ, Reid KM, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140:491\u2013503.","journal-title":"Blood"},{"key":"3081_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/2326-6066.CIR-22-0095","volume":"11","author":"GM Chen","year":"2023","unstructured":"Chen GM, Chen C-H, Perazzelli J, Grupp SA, Barrett DM, Tan K. Characterization of leukemic resistance to CD19-targeted CAR T-cell therapy through deep genomic sequencing. Cancer Immunol Res. 2023;11:13\u201319.","journal-title":"Cancer Immunol Res"},{"key":"3081_CR50","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.24594","volume":"92","author":"H Yu","year":"2017","unstructured":"Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL, et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol. 2017;92:E11\u2013E13.","journal-title":"Am J Hematol"},{"key":"3081_CR51","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood-2010-12-326694","volume":"118","author":"AH Nwabo Kamdje","year":"2011","unstructured":"Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G, et al. Notch-3 and Notch-4 signaling rescue human B-ALL cells from apoptosis in contact with human bone marrow-derived mesenchymal stromal cells. Blood. 2011;118:380\u20139.","journal-title":"Blood"},{"key":"3081_CR52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41568-024-00750-2","volume":"24","author":"O Anczukow","year":"2024","unstructured":"Anczukow O, Allain FH-T, Angarola BL, Black DL, Brooks AN, Cheng C, et al. Steering research on mRNA splicing in cancer towards clinical translation. Nat Rev Cancer. 2024;24:887\u2013905.","journal-title":"Nat Rev Cancer"},{"key":"3081_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02411-1","volume":"22","author":"L Schulz","year":"2021","unstructured":"Schulz L, Torres-Diz M, Cort\u00e9s-L\u00f3pez M, Hayer KE, Asnani M, Tasian SK, et al. Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts. Genome Biol. 2021;22:190.","journal-title":"Genome Biol"},{"key":"3081_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14844-6","volume":"11","author":"B Werner","year":"2020","unstructured":"Werner B, Case J, Williams MJ, Chkhaidze K, Temko D, Fern\u00e1ndez-Mateos J, et al. Measuring single-cell divisions in human tissues from multi-region sequencing data. Nat Commun. 2020;11:1035.","journal-title":"Nat Commun"},{"key":"3081_CR55","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"3081_CR56","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","volume":"140","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, et al. CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140:451\u201363.","journal-title":"Blood"},{"key":"3081_CR57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10:552\u201367.","journal-title":"Cancer Discov"},{"key":"3081_CR58","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020;135:597\u2013609.","journal-title":"Blood"},{"key":"3081_CR59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, et al. A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11:599\u2013613.","journal-title":"Cancer Discov"},{"key":"3081_CR60","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/2643-3230.BCD-24-0176","volume":"6","author":"F L\u00fc\u00f6nd","year":"2025","unstructured":"L\u00fc\u00f6nd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, et al. DLBCL cells emerge after CD19 CAR T cells with cross-antigen resistance and a gene signature predictive of clinical CAR T-cell response. Blood Cancer Discov. 2025;6:580\u2013601.","journal-title":"Blood Cancer Discov"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03081-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:02:41Z","timestamp":1787846561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03081-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":60,"alternative-id":["3081"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03081-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The genetic analysis of human-origin samples was approved by the Ethics Committee for Research of La Paz University Hospital (PI-3007). Informed consent was obtained from all patients or their legal guardians.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}